Advanced solid tumours Cancer Malignant neoplasm of other and ill-defined sites
Conditions
Interventions
Cohorts of 3 to 6 patients will receive ONX 0801 at escalating doses until a maximum tolerated dose (MTD) is determined. Each patient will receive a 3-hour intravenous (IV) infusion of ONX 0801 weekly
Sponsors
Onyx Pharmaceuticals (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically proven solid tumours, including lymphomas. Patients must have disease which has failed standard therapy or for which no standard curative therapy exists. 2. Greater than or equal to 18 years of age, either sex 3. Eastern Cooperative Oncology Group performance status (ECOG PS) less than or equal to 2 4. Life expectancy greater than or equal to 12 weeks 5. Measurable (as defined by Response Evaluation Criteria in Solid Tumours [RECIST version 1.1]) or evaluable (based on radiological assessments or tumour markers) disease 6. Recovered (i.e., to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Version 3.0 Grade less than or equal to 1) from all toxicities associated with previous chemotherapy or radiotherapy (exception: patients may enter with continuing alopecia irrespective of CTCAE grade). The following intervals between starting last treatment and starting ONX 0801 must elapse: 6.1. Chemotherapy (see exception below): at least 4 weeks 6.2. Mitomycin C or a nitrosourea: at least 6 weeks 6.3. Targeted therapy: at least 2 weeks or 2 half-lives, whichever is longer 6.4. Biologics: at least 4 weeks 6.5. Radiotherapy: at least 4 weeks 7. Normal organ function 8. Normal electrocardiogram (ECG) 9. Archival tumour tissue available
Exclusion criteria
Exclusion criteria: 1. Pregnant women, women who are lactating, or women of childbearing potential who are not currently on effective means of birth control 2. History of QT/QTc prolongation, clinically significant ventricular tachycardia, ventricular fibrillation, heart block, myocardial infarction within 1 year, congestive heart failure New York Heart Association Class III or IV, unstable angina, angina within 6 months, or other evidence of clinically significant coronary artery disease 3. Active, ongoing infection, including viral hepatitis 4. Undergone major surgery within the last 4 weeks 5. Organ transplant recipients 6. New brain metastasis. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible as long as the treatment was at least 4 weeks prior to initiation of study drug and baseline brain computed tomography (CT) with contrast or magnetic resonance imaging (MRI) within 2 weeks of initiation of study drug is negative for new brain metastases. 7. Patients who have been on other experimental clinical trials of investigational agents within the last 28 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of ONX 0801 based on dose limiting toxicities (DLTs) occurring within cycle 1 2. To characterise the safety profile of ONX 0801 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Pharmacokinetics (PK) of ONX 0801: Blood samples will be collected according to the following schedule: 1.1. Cycle 1, Day 1: predose and 30 minutes and 1, 2, 3, 3.5, 4, 6, 8, 12, 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours following the start of the infusion 1.2. Cycle 1, Days 8 and 15: predose and 3 hours following the start of the infusion 1.3. Cycle 2, Days 1 and 8: predose and 3 hours following the start of the infusion 2. Pharmacodynamics of ONX 0801: 2.1. Blood samples will be collected according to the following schedule: predose and 4, 8, 24 (Day 2), 48 (Day 3), and 72 (Day 4) hours following the start of infusion in Cycle 1, Day 1 and approximately every 6 - 9 weeks during the course of the study 2.2. Tissue samples may be collected predose and up to 72 hours following the start of the infusion in Cycle 1, Day 1 2.3. 18FLT-PET scans may be performed predose and between 16 to 48 hours following the start of the infusion in Cycle 1, Day 1 3. Identifying a biologically effective dose (BED) equal to or lower than the MTD and/or RP2D of ONX 0801 4. Assess the preliminary antitumour activity of ONX 0801 | — |
Countries
United Kingdom
Outcome results
None listed